TheraCryf (LSE:TCF) Institutional Ownership : 0.56% (As of Apr. 29, 2025)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TheraCryf's institutional ownership is 0.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TheraCryf's Insider Ownership is 2.22%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TheraCryf's Float Percentage Of Total Shares Outstanding is 0.00%.

TheraCryf Institutional Ownership Historical Data

The historical data trend for TheraCryf's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Institutional Ownership Chart

TheraCryf Historical Data

The historical data trend for TheraCryf can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	3.94	3.94	3.94	3.94	2.77	2.76	2.76	2.76	2.33	0.56

TheraCryf Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

TheraCryf Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG

Website

https://www.evgen.com

TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.